PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-12.50%
Both companies reducing costs. Martin Whitman would check industry efficiency trends.
12.50%
Positive growth while AGEN shows decline. John Neff would investigate competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
37.48%
R&D growth while AGEN reduces spending. John Neff would investigate strategic advantage.
21.30%
G&A growth while AGEN reduces overhead. John Neff would investigate operational differences.
100.00%
Similar marketing expense growth to AGEN's 100.00%. Walter Schloss would investigate industry requirements.
No Data
No Data available this quarter, please select a different quarter.
32.37%
Operating expenses growth while AGEN reduces costs. John Neff would investigate differences.
29.39%
Total costs growth while AGEN reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
-12.50%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-30.36%
EBITDA decline while AGEN shows 35.69% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-29.39%
Operating income decline while AGEN shows 8.18% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
14.89%
Similar other expenses growth to AGEN's 19.52%. Walter Schloss would investigate industry patterns.
-30.95%
Pre-tax income decline while AGEN shows 13.64% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Tax expense reduction while AGEN shows 100.00% growth. Joel Greenblatt would examine advantage.
-30.95%
Net income decline while AGEN shows 14.23% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-22.58%
EPS decline while AGEN shows 17.11% growth. Joel Greenblatt would examine position.
-22.58%
Diluted EPS decline while AGEN shows 17.11% growth. Joel Greenblatt would examine position.
7.95%
Share count reduction below 50% of AGEN's 3.41%. Michael Burry would check for concerns.
7.95%
Diluted share reduction below 50% of AGEN's 3.41%. Michael Burry would check for concerns.